Anatara Lifesciences Ltd (ASX:ANR) Quarterly Report
Brisbane, Oct 31, 2018 - (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to release its Appendix 4C for the quarter ending 30th September 2018. The Company's cash position at the end of the quarter stood at $7.1m.
During the reporting period, Anatara received income of USD 500k, which was the remainder of the upfront payment from Zoetis Inc, that was paid upon execution of the exclusive licensing agreement for the worldwide development, manufacture, distribution and marketing of Detach, signed in May 2018. Expenditure during the quarter was in line with forecast.
Post the quarter, on the 23rd October, Anatara announced the appointment of a new Product Development Advisory Board comprising prominent independent experts in human gastrointestinal health. The group will assist the company in the development of its human health products.
Also post the quarter, on the 29th October, Anatara announced that it had received approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) for its animal health product, Detach with the approved label, "To aid in the control of scour and has positive health benefits in weaned piglets from 3 weeks of age and help increase survivability of scouring pre-weaning piglets".
The Company remains sufficiently funded to execute on the development and partnering of our Gastrointestinal ReProgramming (GaRP) dietary supplement, designed to address the primary underlying factors associated with gastrointestinal disorders such as Irritable Bowel Syndrome and Inflammatory Bowel Disease.
WEB: Appendix 4C - quarterly
About: Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) develops and aims to partner non-antibiotic, oral products for gastrointestinal diseases in animals and humans where there is significant unmet need and large market opportunity. In May 2018, Anatara granted an exclusive licence to the leading global animal health company, Zoetis Inc., for the worldwide development, manufacturing, distribution and marketing of its lead product Detach as a non-antibiotic approach to aid in the control of diarrhoeal disease (known as scour) in livestock and in horses. Anatara is now focused on developing its human product pipeline for gastrointestinal health applications. For more information, please visit www.anataralifesciences.com
Contact:
Investor inquiries
Sue MacLeman
Chair
Anatara Lifesciences
T: +61-437-211-200
E: smacleman@anatara.com
Media inquiries:
Jane Lowe
IR Department
T: +61-411-117-774
E: jane.lowe@irdepartment.com.au